Growth Hormone & Igf Research最新文献

{"title":"Dental arches in inherited severe isolated growth hormone deficiency","authors":"Rafaela S. Girão ,&nbsp;Manuel H. Aguiar-Oliveira ,&nbsp;Bruna M.R. Andrade ,&nbsp;Marcos A.V. Bittencourt ,&nbsp;Roberto Salvatori ,&nbsp;Evânio V. Silva ,&nbsp;André L.M. Santos ,&nbsp;Matheus M. Cunha ,&nbsp;Wilton M. Takeshita ,&nbsp;Alaíde H.A. Oliveira ,&nbsp;Eugênia H.O. Valença ,&nbsp;Alécia A. Oliveira-Santos ,&nbsp;Luiz A. Oliveira-Neto","doi":"10.1016/j.ghir.2022.101444","DOIUrl":"10.1016/j.ghir.2022.101444","url":null,"abstract":"<div><h3>Objectives</h3><p><span>The growth of the dental arches depends on GH and insulin-like growth factor type 1 (IGF1), but the consequences of GH deficiency (GHD) on their growth are still unclear, probably due to the acquired etiology of GHD in most described series, often associated with additional pituitary deficits (thyrotrophic, corticotrophic and gonadotrophic hormones), and imperfections of related replacement therapies, which may affect the dental arch growth. To avoid these limitations, we took advantage of a unique cohort of subjects with isolated GH deficiency (IGHD) due the same mutation in the </span>GH releasing hormone<span> receptor gene<span>, living with very low serum GH and low to undetectable circulating IGF1 levels. Our purpose was to analyze the dimensions of maxillary and mandibular dental arches.</span></span></p></div><div><h3>Methods</h3><p>22 adult IGHD (15 untreated and 7 previously partially treated with GH) and 33 controls were enrolled in a cross-sectional study using the Ortho Insight 3D and MeshMixer software,</p></div><div><h3>Results</h3><p>In untreated IGHD subjects all maxillary arch measures were smaller than controls, while among mandibular arches, only the mandibular canine<span><span> width and the mandibular arch length were reduced. In partially GH treated subjects only the palate depth, the </span>maxillary canine width, the maxillary and mandibular arch lengths remained smaller than controls.</span></p></div><div><h3>Conclusions</h3><p>IGHD reduces the growth of maxillary arch to a greater degree than the mandibular arch, suggesting different control of superior and inferior dental arches. GH treatment increases some of these measures.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101444"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39912507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regulation of 11β-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients","authors":"Stuart A. Morgan ,&nbsp;Darlene E. Berryman ,&nbsp;Edward O. List ,&nbsp;Gareth G. Lavery ,&nbsp;Paul M. Stewart ,&nbsp;John J. Kopchick","doi":"10.1016/j.ghir.2021.101440","DOIUrl":"10.1016/j.ghir.2021.101440","url":null,"abstract":"<div><p><span><span>Patients with growth hormone deficiency<span> (GHD) have many clinical features in common with Cushing's syndrome (glucocorticoid excess) – notably visceral obesity, insulin resistance, muscle </span></span>myopathy<span><span> and increased vascular mortality. Within key metabolic tissues, 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) converts cortisone to the active </span>glucocorticoid<span>, cortisol (11-dehydrocorticosterone and </span></span></span>corticosterone in rodents respectively), and thus amplifies local glucocorticoid action.</p><p>We hypothesize that 11β-HSD1 expression is negatively regulated by growth hormone (GH), and that GHD patients have elevated 11β-HSD1 within key metabolic tissues (leading to increased intracellular cortisol generation) which contributes to the clinical features of this disease.</p><p>To identify the impact of GH excess/resistance on 11β-HSD1 <em>in vivo</em><span><span><span>, we measured mRNA expression in key metabolic tissues of giant mice expressing the bovine GH (bGH) gene, dwarf mice with a disrupted </span>GH receptor (GHRKO) gene and mice expressing a gene encoding a GH </span>receptor antagonist<span> (GHA). Additionally, we assessed urine steroid markers of 11β-HSD1 activity in both GHRKO and bGH animals.</span></span></p><p><span>11β-HSD1 expression was decreased in gastrocnemius muscle (0.43-fold, </span><em>p</em><span> &lt; 0.05), subcutaneous adipose (0.53-fold, </span><em>p</em> &lt; 0.05) and epididymal adipose tissue (0.40-fold, <em>p</em> &lt; 0.05), but not liver, in bGH mice compared to WT controls. This was paralleled by an increased percentage of 11-DHC (inactive glucocorticoid) present in the urine of bGH mice compared to WT controls (2.5-fold, <em>p</em> &lt; 0.01) - consistent with decreased systemic 11β-HSD1 activity. By contrast, expression of 11β-HSD1 was increased in the liver of GHRKO (2.7-fold, <em>p</em> &lt; 0.05) and GHA mice (2.0-fold, <em>p</em> &lt; 0.05) compared to WT controls, but not gastrocnemius muscle, subcutaneous adipose tissue or epididymal adipose tissue.</p><p>In summary, we have demonstrated a negative relationship between GH action and 11β-HSD1 expression which appears to be tissue specific. These data provide evidence that increased intracellular cortisol production within key tissues may contribute to metabolic disease in GHD patients.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101440"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39651866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel gross deletion at the LHX4 gene locus in a child with growth hormone deficiency","authors":"Saumya Madushani Samarasinghe ,&nbsp;Tharmini Sundralingam ,&nbsp;Asanka Sudeshini Hewage ,&nbsp;K.S.H. de Silva ,&nbsp;Kamani Hemamala Tennekoon","doi":"10.1016/j.ghir.2021.101443","DOIUrl":"10.1016/j.ghir.2021.101443","url":null,"abstract":"<div><h3>Objective</h3><p>To identify and characterize a novel deletion at the <span><em>LHX4</em></span><span> gene locus<span><span> in a proband with </span>growth hormone deficiency (GHD).</span></span></p></div><div><h3>Methods</h3><p>Long range polymerase chain reaction<span> (PCR) amplification was used to confirm the suspected deletion and to identify the rough locations of the end points. Sanger sequencing was carried out to identify the exact end points of the deletion.</span></p></div><div><h3>Results</h3><p><span>Suspected deletion was confirmed via long range PCR amplification. Sanger sequencing identified the end points of the deletion within three nucleotide repeat sequences (“CTT”). The total length of the deleted segment was 12 127 base pairs and it includes complete exon 5 and exon 6 of the </span><em>LHX4</em><span> gene. Therefore the homeodomain motif coded by exons 4 and 5, might be affected</span><del>.</del></p></div><div><h3>Conclusion</h3><p>We have identified a novel deletion that spans exon 5 and exon 6 of the <em>LHX4</em> gene that could have occurred via microhomology mediated non-recurrent rearrangement. The deletion characterized does not appear to have been reported before. To our knowledge this novel deletion is the first identified <em>LHX4</em><span><span> variant from Sri Lanka and it explains the phenotype of the proband characterized by growth hormone deficiency, hypoplastic anterior pituitary and subsequent deficiency of thyroid stimulating hormone and </span>adrenocorticotropic hormone (ACTH).</span></p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101443"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39888615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personality traits in acromegalic patients: Comparison with patients with non-functioning adenomas and healthy controls","authors":"Elif Kilic Kan ,&nbsp;Aysegul Atmaca ,&nbsp;Gokhan Sarisoy ,&nbsp;Gulcin Cengiz Ecemis ,&nbsp;Feyzi Gokosmanoglu","doi":"10.1016/j.ghir.2021.101439","DOIUrl":"10.1016/j.ghir.2021.101439","url":null,"abstract":"<div><h3>Objectives</h3><p>Pituitary diseases may cause psychiatric and personality alterations. We aimed to compare the personality traits of acromegalic patients with those of patients with non-functioning pituitary adenomas and a healthy control group.</p></div><div><h3>Design</h3><p><span>Fifty-eight acromegalic patients, 45 patients with non-functioning adenoma<span>, and 40 healthy subjects were enrolled in the study. Cloninger's Temperament and Character Inventory (TCI), Beck Depression Inventory, </span></span>Beck Anxiety Inventory, and Rosenberg Self-Esteem Scale (RSES) were used to assess personality, depression, anxiety, and self-esteem.</p></div><div><h3>Results</h3><p><span>Depression score was higher in acromegaly and non-functioning adenoma groups than healthy controls. RSES scores were similar among the three groups. Regarding the scales of TCI, only novelty-seeking was significantly reduced in acromegaly and non-functioning adenoma than the control group. Pairwise comparisons revealed that the difference was due to the difference between acromegalic patients and controls. Scales of TCI were correlated with depression and anxiety </span>in patients with acromegaly and non-functioning adenoma but not in healthy controls.</p></div><div><h3>Conclusion</h3><p>This study showed that novelty-seeking was reduced in patients with acromegaly. Both the hormonal lack and excess and structural changes can lead to cognitive and personality changes in acromegaly. More studies are needed to be carried out about personality characteristics in pituitary diseases.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101439"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39651867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a copper intrauterine device on HLA-G and IGF-II levels during pregnancy","authors":"Lili Cao ,&nbsp;Xiuying Chen ,&nbsp;Lili Huang","doi":"10.1016/j.ghir.2021.101441","DOIUrl":"10.1016/j.ghir.2021.101441","url":null,"abstract":"<div><h3>Objective</h3><p>An intrauterine device (IUD) is one of the most effective reversible contraceptive methods currently available. Women who use IUDs may become pregnant, albeit rarely, and many such women continue to use IUDs. Because it is difficult to remove or it may cause miscarriage. This study measured the changes in human leucocyte antigen-G (HLA-G) and insulin-like growth factor II (IGF-II) levels in the decidua and villi to explore the effect of a copper IUD on embryonic development.</p></div><div><h3>Design</h3><p>A total of 54 samples of decidual and villus tissue were collected from pregnant women with IUDs (27 samples) or without IUDs (27 samples). Hematoxylin-eosin staining was used to identify morphological characteristics. Immunohistochemistry was used to detect HLA-G and IGF-II; the protein expression levels were measured via Western blotting.</p></div><div><h3>Results</h3><p>HLA-G was expressed on the membranes of trophoblasts of villus tissues and the glandular epithelium, and in stromal cells of decidual tissues, in both the IUD and control groups. IGF-II was expressed in the glandular epithelium and cytoplasm of trophoblasts and decidual cells in both groups. Compared to the control group, IGF-II expression was significantly reduced in villus tissues of the IUD group (p &lt; 0.05). The mean sac diameter was significantly positively correlated with IGF-II expression in the villi (<em>p</em> &lt; 0.05).</p></div><div><h3>Conclusions</h3><p>A copper IUD may affect embryonic development by regulating the expression of villus IGF-II.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101441"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1096637421000642/pdfft?md5=1e8c04839a2ab881e9049c5a50c93b00&pid=1-s2.0-S1096637421000642-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39679407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"“Subclinical atherosclerosis in acromegaly: Possible association with cardiovascular risk factors rather than disease activity”","authors":"Maria Cristina Costa de Almeida ,&nbsp;Claudia Maria Vilas Freire ,&nbsp;Maria do Carmo P. Nunes ,&nbsp;Beatriz Santana Soares ,&nbsp;Marcia M. Barbosa ,&nbsp;Alexandre Varella Giannetti ,&nbsp;Giancarlo Pereira Zille ,&nbsp;Paulo Augusto Carvalho Miranda ,&nbsp;Antonio Ribeiro-Oliveira Jr ,&nbsp;Juliana Beaudette Drummond","doi":"10.1016/j.ghir.2021.101442","DOIUrl":"10.1016/j.ghir.2021.101442","url":null,"abstract":"<div><h3>Objective</h3><p>Cardiovascular (CV) disease is still a major cause of excessive morbidity and mortality in patients<span><span><span> with active acromegaly, which may be attributed to a high prevalence of associated pro-atherosclerotic risk factors. However, a direct effect of GH/IGF-1 excess on the </span>vasculature has been previously suggested, warranting further investigation. The present study was designed to investigate whether chronic GH/IGF-1 excess is associated with an increased prevalence of subclinical </span>atherosclerosis in patients with acromegaly.</span></p></div><div><h3>Design</h3><p><span>We measured carotid intima-media thickness (cIMT) and assessed carotid plaques by ultrasonography along with classical CV risk factors in 54 acromegaly patients (34 females, 50 ± 12 years and compared those with 62 (42 females, 53 ± 13 years) age-, sex- and CV risk factors- matched controls. In order to compare cIMT measurements between patients and controls we analyzed </span>common carotid artery far wall data as well as a combined measurement result, which consisted of the mean value of the six different measurements, three at each side.</p></div><div><h3>Results</h3><p><span><span>mean ± SD serum GH and IGF-1 levels were 2.76 ± 4.65 ng/mL and 1.7 ± 1.25 x ULN, respectively, in all acromegaly patients. Age, </span>body mass index<span>, blood pressure, lipid levels, fasting glucose and Framingham's global cardiovascular risk score classification were similar comparing patients and controls. Combined median [IQR] cIMT measurements were similar in acromegaly patients and matched controls (0.59 [0.52–0.66] mm vs. 0.59 [0.52–0.69] mm; </span></span><em>P</em> = 0.872) as well as in acromegaly patients with active and controlled disease (0.59 [0.51–0.68] mm vs. 0.60 [0.54–0.68] mm; <em>P</em> = 0.385). No significant correlations were observed between cIMT measurements and GH (Spearman <em>r</em> = 0.1, <em>P</em> = 0.49) or IGF-1 (Spearman <em>r</em> = 0.13, <em>P</em><span> = 0.37) levels in patients with acromegaly. Carotid atherosclerotic plaques prevalence was similar in patients and controls (26% vs. 32%; </span><em>P</em> = 0.54) as well as in patients with active and controlled acromegaly (22% vs. 30%; <em>P</em> = 0.537).</p></div><div><h3>Conclusions</h3><p>Our data suggest that GH/IGF-1 excess itself is not one of the main drivers of subclinical morphological atherosclerosis changes in patients with acromegaly and that optimal control of acromegaly-associated CV risk factors may preserve vasculature structure even when strict biochemical control is not achieved.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"62 ","pages":"Article 101442"},"PeriodicalIF":1.4,"publicationDate":"2022-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39849349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"David B. Dunger: in memoriam 1948–2021","authors":"KevinC.J. Yuen ,&nbsp;Ken Ong ,&nbsp;Rakesh Amin ,&nbsp;Rachel Williams","doi":"10.1016/j.ghir.2021.101426","DOIUrl":"10.1016/j.ghir.2021.101426","url":null,"abstract":"","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101426"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101426","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89019038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in anterior segment parameters and presence of dry eye disease in patients with acromegaly: A Sirius topography study combined with meibography","authors":"Deniz Kilic ,&nbsp;Berkay Akmaz ,&nbsp;Fahrettin Akay ,&nbsp;Yusuf Ziya Guven ,&nbsp;Guzide Gonca Oruk","doi":"10.1016/j.ghir.2021.101424","DOIUrl":"10.1016/j.ghir.2021.101424","url":null,"abstract":"<div><h3>Purpose</h3><p><span>To investigate anterior segment parameters (ASPs) and dry eye disease (DED), including the status of the meibomian glands, </span>in patients<span> with acromegaly.</span></p></div><div><h3>Methods</h3><p><span>In this cross-sectional, comparative study, 36 acromegaly patients and 40 healthy sex- and age-matched controls were included. Participants received a comprehensive ophthalmological examination, including intraocular pressure<span> measurements with Goldmann applanation tonometry (IOP</span></span>_GAT) and central corneal thickness corrected intraocular pressure (IOP_CCT<span>) measurements, and were evaluated for ASPs and DED. For ASPs, white-to-white (WTW), apical (ACT) and thinnest corneal thickness (TCT), corneal volume (CV), keratometry readings (K</span>₁, K₂, and K_mean<span><span><span>), anterior chamber depth (ACD) and volume (ACV), and iridocorneal angle (ICA) were obtained via Sirius topography. DED was assessed with Schirmer's test, tear breakup time (TBUT), and </span>Ocular Surface Disease Index (OSDI) scores. </span>Meibography scores (MSs) were obtained with the Sirius topography device.</span></p></div><div><h3>Results</h3><p>Patients had higher mean IOP_GAT (<em>P</em> = .006), IOP_CCT (<em>P</em> = .01), ACT (<em>P</em> = .024), and TCT (<em>P</em> = .005) but narrower ICA (<em>P</em> = .014) than controls. Although Schirmer's test did not differ between the groups (<em>P</em> = .442), patients had higher OSDI (<em>P</em> &lt; .001), higher MS (<em>P</em> = .001), and shorter TBUT (<em>P</em> = .002).</p></div><div><h3>Conclusion</h3><p>Patients with acromegaly have greater IOP, greater corneal thickness, but narrower ICA than healthy individuals, as well as DED with increased MSs, which suggests meibomian gland dysfunction.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101424"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101424","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39320895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and epidemiological characteristics, morbidity and treatment based on the registry of acromegalic patients in Colombia: RAPACO","authors":"Rafael Castellanos-Bueno ,&nbsp;Alín Abreu-Lomba ,&nbsp;Nathalia Buitrago-Gómez ,&nbsp;Marcela Patiño-Arboleda ,&nbsp;Doly Pantoja-Guerrero ,&nbsp;Alex Valenzuela-Rincón ,&nbsp;Henry M. Arenas-Quintero ,&nbsp;Humberto I. Franco-Betancur ,&nbsp;Alejandro Castellanos-Pinedo ,&nbsp;Dinett Movilla-Castro ,&nbsp;José M. Ocampo-Chaparro ,&nbsp;Carlos A. Reyes-Ortiz ,&nbsp;Alejandro Pinzón-Tovar","doi":"10.1016/j.ghir.2021.101425","DOIUrl":"10.1016/j.ghir.2021.101425","url":null,"abstract":"<div><h3>Aims</h3><p>Describe the local characteristics, methodology and results of the registry of acromegalic patients in Colombia (RAPACO).</p></div><div><h3>Methods</h3><p>Multicenter, retrospective study based on the registry of acromegalic patients in Colombia: RAPACO. The data collected included: demographics, diagnosis, approximate time of disease evolution, data on weight, height, body mass index<span><span> (BMI), neck circumference<span> (NC) abdominal circumference<span> (AC) hip circumference (HC) and waist/hip ratio (WHR); clinical and biochemical data at the time of diagnosis, etiology, </span></span></span>immunohistochemistry<span> of the tumor and information related to types of treatment. Descriptive analytics were employed.</span></span></p></div><div><h3>Results</h3><p>A total of 201 patients (60% females) with an average age at registration of 49.5 ± 14.6 years and an average time of evolution of the disease of 6.96 ± 4.5 years. Average weight was 75.1 Kg ± 12.98, with an average BMI of 28.11 ± 4.33. The most frequent symptoms mentioned at the time of diagnosis were extremity enlargement and headache. The most frequent comorbidity was arterial hypertension in 50.3% of the cases. 78.6% of cases were caused by macroadenoma<span>. 80.1% received surgical treatment, 77.6% were under medical treatment, of which 95.7% were receiving somatostatin analogues. 26.4% of patients were treated with radiation therapy. Of the patients who received any type of clinical treatment, only 2.5% reported biochemical control at registration.</span></p></div><div><h3>Conclusion</h3><p>It is important to recognize the local epidemiological, clinical, biochemical and treatment characteristics in order to assist in further understanding this pathology to implement local measures to improve both the quality of life as well as the prognosis of the patients diagnosed.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101425"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101425","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39330066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Illness-related burden, personal resources and need for support in patients with acromegaly: Results of a focus group analysis","authors":"Sonja Siegel ,&nbsp;Cedric Fabian Kirstein ,&nbsp;Bernadette Schröder ,&nbsp;Nicole Unger ,&nbsp;Ilonka Kreitschmann-Andermahr","doi":"10.1016/j.ghir.2021.101422","DOIUrl":"10.1016/j.ghir.2021.101422","url":null,"abstract":"<div><h3>Objective</h3><p><span>It was the aim of this study to evaluate illness-related burdens and support needs of patients with acromegaly to identify hitherto unadressed research questions and to open up avenues for improvements </span>in patient care. This was done by using the focus group approach as a qualitative research method.</p></div><div><h3>Design</h3><p>Seven patients with acromegaly took part in a focus group moderated by an external medical communication specialist. The discourse focused on topics such as impact of the illness on everyday life, support needs and personal resources. The discussion was recorded and transcribed and analyzed by qualitative content analysis.</p></div><div><h3>Results</h3><p>Participants reported a huge impact of acromegaly on daily life, ranging from time expenditure for managing their illness, to bodily and mental sequelae<span><span> and strain caused by physical disfigurement. Patients' coping strategies included family support, physical activities and humor. The participants wished for a sound patient-doctor relationship, more interdisciplinary and holistic </span>treatment, medical rehabilitation services with special knowledge on acromegaly-related morbidity, a stable contact person in the medical process and reliable information material for themselves and their relatives.</span></p></div><div><h3>Conclusions</h3><p>The results provide multi-facetted impressions of the overwhelming impact of acromegaly and unmet support needs of the afflicted patients. Further quantitative research is necessary to examine the generalisibility of the present results in order to implement tailored support measures. We suggest to develop standardized questionnaires to explore the prevalence and severity of the addressed problems in a large patient sample and to establish screening instruments to monitor disease burden in clinical practice.</p></div>","PeriodicalId":12803,"journal":{"name":"Growth Hormone & Igf Research","volume":"60 ","pages":"Article 101422"},"PeriodicalIF":1.4,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ghir.2021.101422","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39332552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}